Ulcerative colitis
Conditions
Interventions
Placebo group(Phase of activity):Maltodextrin 5g/d
Intervention group-Albumin oligomeric peptide group(Phase of activity):Albumin oligomeric peptide 5g/d
Intervention group-Fish skin collagen oligopeptide group(Phase of activity):Fish skin collagen oligopeptide 5g/d
Blank control group(Phase of activity):None
Intervention group-Albumin oligomeric peptide group(Phase of remission):Albumin oligomeric peptide 5g/d
Intervention group-Fish skin collagen oligopeptide group(Phase of remission):Fish skin collagen oligopeptide 5g/d
Blank control group(Phase of remission):None
Sponsors
Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with ulcerative colitis diagnosed through clinical, endoscopic, radiological, and histological criteria; 2. Aged between 18-80 years; 3. Patients in remission are defined as having a modified Mayo score of =3; 4. Prior to enrollment, stable doses of maintenance therapy for ulcerative colitis are required: oral stable aminosalicylates, at least 3g mesalamine or equivalent medications, not exceeding 4.8g; before baseline, corticosteroids must be taken at <=20mg or equivalent medications (which can be gradually reduced according to clinical needs), with azathioprine taken for 6 weeks or biologics for 8 weeks; 5. Non-steroidal anti-inflammatory drugs, probiotics, prebiotics, enteral nutrition products, etc., cannot be used for 1 month prior to enrollment; 6. Voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Concurrent severe liver, heart, lung, or kidney diseases; 2. Abdominal abscess, toxic megacolon, partial or total colonic resection, unresected adenomatous colonic polyps, or colonic mucosal dysplasia; 3. Obese patients (BMI > 27.9 kg/m^2), patients with metabolic syndrome, malignancies, and/or metabolic diseases (such as hyperthyroidism, diabetes); 4. Pregnant or breastfeeding individuals; 5. Taking more than 20 mg of oral prednisone or equivalent medications, using methotrexate, or subjects not receiving treatment; 6. Known allergy to fish skin collagen oligopeptides and albumin oligopeptides.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Mayo score;Clinical recurrence occurred within 6 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory Bowel Disease Questionnaire, IBDQ;Ulcerative Colitis Endoscopic Index of Severity (UCEIS);Blood biochemical index;Fecal Microbiota;Colonic mucosal barrier function;Metabolome;Body Composition Analysis;Blood inflammatory factors;Fecal calprotectin; | — |
Countries
China
Contacts
Public ContactWang Dandan
Affiliated Hospital of Qingdao University
Outcome results
None listed